LOX and colorectal adenocarcinoma: There are increasing reports demonstrating the promising effect of targeting hypoxia-responsive genes, such as LOX, LOXL2, and VEGFA. For instance, a couple of drugs targeting LOX family members are in the early stage of clinical trials [5], including pancreatic and colorectal adenocarcinoma [10,11].